Takeda Pharmaceutical (TAK) Revenue (2017 - 2026)

Takeda Pharmaceutical has reported Revenue for 10 years, with the latest figure at $7.7 billion in Q2 2026.

• On a quarterly basis, Revenue changed 0.07% year-over-year to $7.7 billion in Q2 2026; TTM through Jun 2026 was $46.5 billion, a 0.74% increase from a year earlier, with the FY2026 full-year figure at $28.7 billion, down 4.48% from the prior year.
• Revenue was $7.7 billion for Q2 2026 at Takeda Pharmaceutical, down from $7.8 billion in the prior quarter.
• The five-year high for Revenue was $23.9 billion in Q3 2025, with the low at $6.9 billion in Q4 2024.
• Average Revenue over 5 years is $10.3 billion, with a median of $7.8 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Revenue dropped 13.32% in 2022, then soared 206.56% in 2023.
• Over 5 years, Revenue stood at $7.8 billion in 2022, then fell by 8.4% to $7.1 billion in 2023, then declined by 2.54% to $6.9 billion in 2024, then gained by 2.64% to $7.1 billion in 2025, then grew by 7.62% to $7.7 billion in 2026.
• The last three Revenue figures came in at $7.7 billion (Q2 2026), $7.8 billion (Q1 2026), and $7.1 billion (Q4 2025), per Business Quant data.